Clinical Trials for Pancreas Cancer

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic solid tumors potentially expressing CLDN18.2—including gastric/GEJ, pancreatic, esophageal, and biliary tract cancers—or other tumors with documented CLDN18.2 expression receive IV BL-M05D1 every 21 days. BL-M05D1 is a CLDN18.2-targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT07021066

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For adults with nonmetastatic, locally advanced pancreatic adenocarcinoma after 4–6 months of induction chemotherapy, this study evaluates five-fraction hypofractionated radiotherapy with oral peposertib or placebo. Peposertib inhibits DNA-dependent protein kinase to impair repair of radiation-induced DNA damage.

ClinicalTrials.gov ID: NCT04172532

Phase 1 Clinical Trial of Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, nonmetastatic locally advanced pancreatic ductal adenocarcinoma who have received at least four months of chemotherapy and have a tumor suitable for complete ablation undergo surgical irreversible electroporation with intratumoral mitazalimab. Mitazalimab is an investigational CD40 agonist antibody intended to stimulate antitumor immune responses.

ClinicalTrials.gov ID: NCT06205849

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ersodetug in Patients With Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (tHI)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with insulin- or IGF-secreting tumors and hypoglycemia inadequately controlled by usual care receive IV ersodetug, an investigational insulin receptor antibody that reversibly reduces insulin signaling, while continuing existing care. Ambulatory patients with insulin-secreting tumors are randomized to ersodetug or placebo; hospitalized patients and ambulatory patients with IGF-secreting tumors receive ersodetug.

ClinicalTrials.gov ID: NCT06881992

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma and homozygous MTAP deletion receive AMG 193, an MTA-cooperative PRMT5 inhibitor, with gemcitabine/nab-paclitaxel or modified FOLFIRINOX. A separate cohort with RAS-mutant disease and prior systemic therapy receives AMG 193 with RMC-6236, a multiselective RAS(ON) inhibitor.

ClinicalTrials.gov ID: NCT06360354

A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory pancreatic ductal adenocarcinoma who have received standard therapy and have an ECOG performance status of 0–1 receive lymphodepleting chemotherapy followed by autologous B7-H3–targeted CAR-T cells. The cells contain an inducible caspase-9 safety switch that can be activated with rimiducid if serious toxicity occurs.

ClinicalTrials.gov ID: NCT06158139

A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated, unresectable locally advanced or metastatic exocrine pancreatic adenocarcinoma and ECOG 0–1 receive first-line NALIRIFOX plus oral onvansertib, an investigational PLK1 inhibitor that disrupts mitosis.

ClinicalTrials.gov ID: NCT06736717

A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal adenocarcinoma progressing after 1–2 prior systemic lines, or pancreatic ductal adenocarcinoma progressing after exactly 1 prior line, receive GSK5764227 at cohort-specific dose levels. GSK5764227 is an investigational B7-H3–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06885034

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable metastatic or locally advanced head and neck, lung, gastrointestinal, pancreatic, cervical, endometrial, or urothelial cancer receive STRO-004 alone or with pembrolizumab. STRO-004 is a tissue factor–targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT07227168

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable MTAP-deleted advanced solid tumors (ECOG 0–1) receive oral IDE892 alone or with IDE397; dose-expansion cohorts are limited to NSCLC. IDE892 is an MTA-cooperative PRMT5 inhibitor, and IDE397 is a MAT2A inhibitor.

ClinicalTrials.gov ID: NCT07277413